Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.
Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
BMC Med. 2024 Jun 10;22(1):233. doi: 10.1186/s12916-024-03447-3.
Among patients diagnosed with schizophrenia, the presence of substance use poses an aggravating comorbidity, exerting a negative impact on the course of the disease, adherence to therapeutic regimens, treatment outcomes, duration of hospital stays, and the frequency of hospitalizations. The primary objective of the present study is to investigate the relationship between comorbid substance use disorders, antipsychotic treatment, and the length of stay in individuals hospitalized for treatment of schizophrenia.
We conducted a retrospective analysis of electronic health records spanning a 12-month period, specifically focusing on adult patients diagnosed with schizophrenia who were discharged from the University Hospital of Psychiatry Zurich between January and December 2019. We documented the number and types of diagnosed substance use disorder, the antipsychotic treatment, the length of stay, and the number of previous hospitalizations for each patient.
Over a third (n = 328; 37.1%) of patients with schizophrenia had comorbid substance use with cannabis being the most frequent consumed substance. Patients with substance use (either single or multiple) were more frequently hospitalized; those with multiple substance use more frequently than those with a single substance use (F(2, 882) = 69.06; p < 0.001). There were no differences regarding the rate of compulsory admission. Patients with no substance use had a lower HoNOS score at discharge (F(2, 882) = 4.06). Patients with multiple substance use had a shorter length of stay (F(2, 882) = 9.22; p < 0.001), even after adjusting for duration of illness, previous hospitalizations, diagnosis, and antipsychotic treatment.
In patients with schizophrenia, comorbid single or multiple substance use has a relevant negative impact on treatment and thus on the course of disease. Substance use in patients with schizophrenia should therefore receive special attention in order to reduce re-hospitalization rates and improve the clinical outcome.
在诊断为精神分裂症的患者中,物质使用的存在构成了一种加重的共病,对疾病过程、治疗方案的依从性、治疗结果、住院时间和住院频率产生负面影响。本研究的主要目的是调查共患物质使用障碍、抗精神病治疗与因精神分裂症住院患者住院时间之间的关系。
我们对 12 个月的电子健康记录进行了回顾性分析,专门针对 2019 年 1 月至 12 月期间从苏黎世大学精神病院出院的被诊断为精神分裂症的成年患者。我们记录了每位患者的物质使用障碍数量和类型、抗精神病治疗、住院时间和先前住院次数。
超过三分之一(n=328;37.1%)的精神分裂症患者共患物质使用障碍,最常使用的物质是大麻。有物质使用障碍(无论是单一的还是多种的)的患者更频繁地住院;有多种物质使用障碍的患者比有单一物质使用障碍的患者更频繁住院(F(2, 882)=69.06;p<0.001)。在强制入院率方面没有差异。无物质使用的患者出院时 HoNOS 评分较低(F(2, 882)=4.06)。有多种物质使用障碍的患者住院时间较短(F(2, 882)=9.22;p<0.001),即使在校正了病程、先前住院次数、诊断和抗精神病治疗后也是如此。
在精神分裂症患者中,单一或多种共患物质使用对治疗有显著的负面影响,从而影响疾病过程。因此,精神分裂症患者的物质使用应受到特别关注,以降低再住院率并改善临床结局。